Navigating Treatment Decisions in Relapsed NPM1-Mutant AML: Practical Insights for Clinical Care

Dr Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) in this Treating Together podcast. The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options.

Dr Roboz emphasized the importance of comprehensive mutational reassessment at relapse, as co-mutation profiles can change from initial diagnosis. She distinguished between mutational profiling for treatment selection versus minimal residual disease (MRD) monitoring, noting that NPM1 was previously considered undruggable but now has 2 FDA-approved menin inhibitors: revumenib and ziftomenib.

Key Clinical Considerations:

• Treatment selection must consider prior therapy exposure, current mutational landscape, and patient access to targeted agents

• Co-mutations (FLT3, IDH1/2) complicate treatment decisions, with sequencing often preferred over combination therapy outside clinical trials

• Single-agent menin inhibitors achieve approximately 25% complete remission rates but limited durability

• Combination approaches with hypomethylating agents (HMA) and venetoclax improve response rates

• Goals of therapy are also important considerations: palliative versus curative intent influences treatment intensity

Safety management focuses on differentiation syndrome monitoring and QT prolongation surveillance. Dr Roboz stressed that differentiation syndrome requires early steroid intervention rather than drug discontinuation, whereas QT monitoring, though important, has not been a major clinical problem in practice.

For transplant-eligible patients, the physicians discussed bridging strategies using HMA-venetoclax-menin inhibitor combinations, emphasizing the importance of achieving MRD negativity when possible without delaying transplant procedures. Looking forward, both experts envision NPM1-mutant AML becoming increasingly curable without transplant, similar to chronic myeloid leukemia, through time-limited targeted therapy approaches with excellent MRD monitoring becoming standard practice across all clinical settings.